Animal models of sepsis and its complications

被引：41

作者：

Fink, Mitchell P. ^{[1
,2
,3
,4
]}

机构：

[1] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15261 USA

[2] Log Therapeut Inc, Waltham, MA USA

[3] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15261 USA

[4] Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA

来源：

KIDNEY INTERNATIONAL | 2008年 / 74卷 / 08期

关键词：

D O I：

10.1038/ki.2008.442

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Most currently used animal sepsis models fail to adequately replicate the clinical problem and, therefore, have only limited utility for investigating pathophysiological mechanisms or testing the efficacy of new therapeutic agents. Recent experimental findings support this view and suggest that models of acute infection in mice with pre-existing renal dysfunction may be useful in the development pathway for new therapeutic agents for sepsis.

引用

收藏

页码：991 / 993

页数：4

相关论文

共 17 条

[1] Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care [J].

Angus, DC ;

Linde-Zwirble, WT ;

Lidicker, J ;

Clermont, G ;

Carcillo, J ;

Pinsky, MR .

CRITICAL CARE MEDICINE, 2001, 29 (07) :1303-1310

[2]

Bagshaw SM, 2008, CRIT CARE, V12, DOI [10.1186/cc6268, 10.1186/cc6863]

[3] Septic acute kidney injury in critically ill patients: Clinical characteristics and outcomes [J].

Bagshaw, Sean M. ;

Uchino, Shigehiko ;

Bellomo, Rinaldo ;

Morimatsu, Hiroshi ;

Morgera, Stanislao ;

Schetz, Miet ;

Tan, Ian ;

Bouman, Catherine ;

Macedo, Ettiene ;

Gibney, Noel ;

Tolwani, Ashita ;

Oudemans-van Straaten, Heleen M. ;

Ronco, Claudio ;

Kellum, John A. .

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 2 (03) :431-439

[4] Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].

Bernard, GR ;

Vincent, JL ;

Laterre, P ;

LaRosa, SP ;

Dhainaut, JF ;

Lopez-Rodriguez, A ;

Steingrub, JS ;

Garber, GE ;

Helterbrand, JD ;

Ely, EW ;

Fisher, CJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709

[5] Challenge and rechallenge: Drotrecogin alfa (activated)-induced prolongation of activated partial thromboplastin time in a patient with severe sepsis [J].

Castelli, EE ;

Culley, CM ;

Fink, MR .

PHARMACOTHERAPY, 2005, 25 (08) :1147-1150

[6] Drotrecogin alfa (activated) in severe sepsis: A systematic review and new cost-effectiveness analysis [J].

Costa V. ;

Brophy J.M. .

BMC Anesthesiology, 7 (1)

[7] Pre-existing renal disease promotes sepsis-induced acute kidney injury and worsens outcome [J].

Doi, Kent ;

Leelahavanichkul, Asada ;

Hu, Xuzhen ;

Sidransky, L. ;

Zhou, Hua ;

Qin, Yan ;

Eisner, Christoph ;

Schnermann, Juegen ;

Yuen, Peter S. T. ;

Star, Robert A. .

KIDNEY INTERNATIONAL, 2008, 74 (08) :1017-1025

[8] Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study [J].

Kanji, Salmaan ;

Perreault, Marc M. ;

Chant, Clarence ;

Williamson, David ;

Burry, Lisa .

INTENSIVE CARE MEDICINE, 2007, 33 (03) :517-523

[9] Understanding the inflammatory in pneumonia and sepsis - Results of the genetic and inflammatory markers of sepsis (GenIMS) study [J].

Kellum, John A. ;

Kong, Lan ;

Fink, Mitchell P. ;

Weissfeld, Lisa A. ;

Yealy, Donald M. ;

Pinsky, Michael R. ;

Fine, Jonathan ;

Krichevsky, Alexander ;

Delude, Russell L. ;

Angus, Derek C. .

ARCHIVES OF INTERNAL MEDICINE, 2007, 167 (15) :1655-1663

[10] 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference [J].

Levy, MM ;

Fink, MP ;

Marshall, JC ;

Abraham, E ;

Angus, D ;

Cook, D ;

Cohen, J ;

Opal, SM ;

Vincent, JL ;

Ramsay, G .

CRITICAL CARE MEDICINE, 2003, 31 (04) :1250-1256